Last reviewed: June 20, 2026
Last updated: June 20, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide and other GLP-1 receptor agonists are not approved for use during pregnancy, and animal studies have raised concerns about fetal development. If you discover you are pregnant while taking Ozempic or a compounded semaglutide injection, stopping the medication and consulting your prescriber immediately is essential. Understanding the risks, timing, and planning options can help you make informed decisions about your health and your family.
GLP-1 Medications and Pregnancy: What the Clinical Evidence Shows
Ozempic and semaglutide have not been studied in pregnant people, and the FDA assigns them Pregnancy Category C status—meaning animal reproduction studies have shown adverse fetal effects, but no human trials exist. In animal models, semaglutide exposure during critical developmental windows has been associated with skeletal abnormalities, delays in fetal development, and reduced fetal weight. These findings do not necessarily predict human outcomes, but they establish enough concern that semaglutide is contraindicated throughout pregnancy.
Tirzepatide (Zepbound), a dual GLP-1/GIP receptor agonist, carries similar pregnancy warnings. Neither medication should be continued if pregnancy is confirmed or suspected. The decision to start or stop these medications requires collaboration between your weight management provider and your obstetrician to ensure the safest plan for both you and your developing baby.
Should You Stop Semaglutide Immediately If You Become Pregnant?
Yes—if you discover you are pregnant, inform your prescriber and obstetrician right away and discontinue semaglutide immediately. Unlike some medications that require a gradual taper, GLP-1 receptor agonists can be stopped without a weaning period, though your provider may recommend a follow-up appointment to discuss any withdrawal effects and adjust your care plan. Most people experience no significant withdrawal symptoms when stopping these medications abruptly.
The first trimester is the period of most critical organ formation, making it especially important to prevent fetal GLP-1 exposure during this time. If you were on semaglutide and only recently discovered pregnancy, inform your healthcare team about the timing and duration of exposure so they can monitor for any potential complications during prenatal screening and ultrasound assessments.
Planning Pregnancy: Timing and GLP-1 Washout Period
If you are considering becoming pregnant, planning in advance with your prescriber can reduce risk. Semaglutide has a half-life of approximately one week, meaning that after stopping the medication, it takes about four to five weeks for the drug to clear from your system almost entirely. Many providers recommend waiting at least one to two menstrual cycles after your last injection before attempting to conceive, giving your body time to eliminate the medication and allowing hormonal regulation to stabilize.
Discussing your pregnancy intentions early allows your weight management team to help you establish sustainable lifestyle habits—nutrition, physical activity, and stress management—that can support healthy weight during pregnancy without pharmacologic support. This proactive approach also gives your obstetrician full context about your recent medication history and any metabolic patterns they should monitor during prenatal care.
Weight Management During Pregnancy Without GLP-1 Therapy
Once you are pregnant, GLP-1 medications cannot be used, but appropriate weight management remains important for maternal and fetal health. Pregnancy is not a time to pursue weight loss; instead, the goal shifts to preventing excessive weight gain while ensuring adequate nutrition for fetal development. Your obstetrician will recommend a calorie intake sufficient for pregnancy (typically 300 additional calories per day in the second and third trimesters) and encourage regular physical activity as tolerated.
Many people who have used semaglutide report improved appetite control and reduced cravings; after stopping, these benefits fade over weeks to months. Rebuilding healthy eating patterns, working with a registered dietitian, and remaining physically active can help manage weight gain during pregnancy. After delivery and the postpartum period, you can discuss restarting GLP-1 therapy with your prescriber if you are not breastfeeding, or planning a future restart after breastfeeding is complete.
PlexusDx Compounded Semaglutide and Reproductive Planning
PlexusDx provides compounded semaglutide injections starting at $149/month from licensed 503A compounding pharmacies, offering an accessible option for those pursuing sustained weight management. If you are a patient using PlexusDx semaglutide and planning to conceive, your PlexusDx provider can coordinate with your obstetrician to ensure a seamless transition off medication and establish a clear timeline for potential restart after pregnancy and postpartum recovery.
PlexusDx also offers the Precision Peptide Genetic Test, which maps 14 metabolic pathways and can reveal genetic insights about your peptide-signaling predispositions. While this test informs your baseline weight management strategy, it cannot predict pregnancy outcomes and should never replace standard prenatal care and discussion with your obstetrician about medication safety and family planning.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What should I do immediately if I find out I'm pregnant while taking semaglutide?
Stop the medication right away and contact both your prescriber and your obstetrician on the same day. Semaglutide can be discontinued without a taper, and your providers need to know the timing and duration of your exposure to plan appropriate prenatal monitoring. Do not wait for a scheduled appointment if you confirm pregnancy.
How long does semaglutide stay in your body after you stop taking it?
Semaglutide has a half-life of approximately one week, meaning half the dose is cleared every seven days. After four to five weeks, most of the medication is eliminated. Many providers recommend waiting one to two menstrual cycles after stopping before attempting conception to ensure complete clearance and hormone stabilization.
Can I restart GLP-1 therapy after pregnancy and delivery?
Yes. After delivery, if you are not breastfeeding, you can discuss restarting GLP-1 therapy with your prescriber once you have medical clearance (typically at your postpartum visit, around six weeks after delivery). If you plan to breastfeed, discuss the safety of specific GLP-1 medications with your obstetrician and pediatrician, as limited data exist on these drugs in breast milk. PlexusDx semaglutide starts at $149/month and is available without insurance.
Is semaglutide completely safe during pregnancy if I use a very low dose?
No. Semaglutide is contraindicated at all doses during pregnancy because animal studies have shown fetal developmental concerns and there are no human safety trials. The FDA classifies it as Pregnancy Category C, meaning it should not be used during pregnancy regardless of dose. Your obstetrician and prescriber should jointly confirm that the medication is stopped as soon as pregnancy is confirmed.
Does the Precision Peptide Genetic Test affect pregnancy planning with GLP-1 therapy?
The Precision Peptide Genetic Test identifies genetic variants in pathways like GLP1R and GIPR that influence your baseline response to weight-loss peptides, but it does not assess pregnancy safety or fetal risk. This test informs your personalized GLP-1 strategy before conception; it should not delay you stopping semaglutide if you become pregnant. Reproductive planning decisions must always involve your obstetrician.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Do You Need a Prescription for Wegovy? Essential Information for Weight Loss Management
Mastering the Ozempic Injection: A Step-by-Step Guide